Vijaya Diagnostic Centre Limited (NSE: VIJAYA, BSE: 543350), one of India's leading integrated diagnostic chains, has reported strong financial performance for the first quarter, along with announcing significant expansion plans across key regions.

Financial Highlights

The company has posted impressive year-on-year growth in its Q1 results:

• Revenue from operations increased by 20.4% to Rs 1,880.50 crore
• EBITDA grew by 20.1% to Rs 735.30 crore, with an EBITDA margin of 39.1%
• Profit after tax (PAT) rose by 22.3% to Rs 383.40 crore, with a PAT margin of 20.4%

Operational Performance

Vijaya Diagnostic also showed strong operational metrics for Q1:

Expansion Plans

Ms. Suprita Reddy, MD & CEO of Vijaya Diagnostic Centre, announced ambitious expansion plans during the earnings call:

1. Near-Term Expansion: The company plans to launch 3 new hubs in Q2 across its core geography and West Bengal.

2. Medium-Term Growth: An additional 2 hubs are scheduled to commence operations in West Bengal by the second half of the fiscal year.

3. Existing Operations: All new hubs in Pune, Bengaluru, and West Bengal are now fully operational with steady footfall.

4. Break-Even Progress: The company remains optimistic about achieving break-even across all centers within 12 months, with one hub in Bengaluru on track to reach break-even earlier than estimated.

5. Recent Success: The Nizamabad hub center has achieved break-even within two quarters of full-fledged operations.

Management Commentary

Commenting on the results and future outlook, Ms. Suprita Reddy stated, "Vijaya reported another strong financial quarter, achieving a YOY growth of 20.4%, with our Hyderabad market's contribution returning to double-digit growth this quarter. The strong performance was largely driven by volume and change in the test mix."

She further added, "Looking ahead, we would be commissioning 3 hubs in Q2 across our Core Geography and West Bengal. The other 2 hubs in West Bengal are also on track to be operationalized in the 2nd half of the fiscal year."

Conclusion

Vijaya Diagnostic Centre's robust Q1 performance, coupled with its aggressive expansion plans, signals the company's strong growth trajectory and commitment to expanding its presence in key markets. As the company continues to focus on both organic growth and strategic expansion, investors and stakeholders will be keenly watching its progress in the coming quarters.

Vijaya Diagnostic Centre , a leading diagnostic services provider, has announced strong financial results for the first quarter of fiscal year 2026, demonstrating significant growth across key metrics.

Revenue Surge

The company reported a substantial increase in its quarterly revenue, which rose to ₹188.05 crore, marking a 20.5% growth compared to ₹156.22 crore in the same period last year. This impressive top-line growth underscores the company's expanding market presence and increasing demand for its diagnostic services.

Profitability Boost

Vijaya Diagnostic Centre's profitability showed remarkable improvement:

• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to ₹73.50 crore from ₹61.20 crore year-over-year.
• The EBITDA margin remained robust at 39.10%, compared to 39.20% in the previous year, indicating consistent operational efficiency.
• Consolidated net profit rose significantly to ₹38.59 crore from ₹31.35 crore in the corresponding quarter of the previous year, representing a growth of 23.1%.

Financial Highlights

Operational Updates

The company's Board of Directors, in their meeting held on July 28, 2025, approved several key operational decisions:

1. Employee Stock Options: The company granted 2,500 Employee Stock Options (ESOPs) under the "VDCL Employee Stock Option Plan 2018". These options are convertible into an equal number of equity shares with a face value of ₹1 each.

2. Secretarial Auditor Appointment: M/s. Balaramakrishna & Associates, Practicing Company Secretaries, have been appointed as the Secretarial Auditor for a period of five consecutive financial years from FY 2025-26 to FY 2029-30.

3. Proposed Merger: The company is progressing with its proposed Scheme of Amalgamation, wherein Medinova Diagnostic Services Limited (a subsidiary) would merge into Vijaya Diagnostic Centre. The scheme is currently awaiting necessary regulatory approvals.

Management Commentary

While specific management comments were not provided, the strong financial performance reflects the company's continued focus on expanding its service offerings and operational efficiency. The consistent EBITDA margin demonstrates Vijaya Diagnostic Centre's ability to manage costs effectively while driving growth.

Vijaya Diagnostic Centre's robust Q1 FY26 results, characterized by double-digit growth in revenue and profitability, position the company well for continued success in the diagnostic services sector. The strategic initiatives, including the proposed merger and employee stock option grants, further underscore the company's commitment to long-term growth and value creation for stakeholders.